Company Overview - Neo-Concept International Group Holdings Limited (NCI) is a one-stop apparel solution services provider, offering a full suite of services in the apparel supply chain, including market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management [1] - NCI sells its own branded apparel products under the brand "Les100Ciels" through retail stores in the UK and UAE, as well as through its e-commerce platform [1] - The company is committed to minimizing its environmental footprint by implementing eco-friendly practices, prioritizing recycling, clean processes, and traceable sourcing [1] Financial Offering - On February 11, 2026, NCI announced the closing of its Follow-On Offering of 14,850,000 Class A ordinary shares at a public offering price of $0.5454 per share, resulting in gross proceeds of approximately $8,000,000 before deducting fees and expenses [1] - The net proceeds from the offering will be utilized for business expansion and general working capital [1] Investment Banking Role - D. Boral Capital LLC acted as the Lead Placement Agent for NCI's Follow-On Offering [1] - D. Boral Capital is a global investment bank that has successfully aggregated approximately $35 billion in capital since its inception in 2020, executing around 400 transactions across various investment banking products [1]

Core Viewpoint - Mainz Biomed N.V. has announced a follow-on offering of 2,000,000 units at an effective price of $2.00 per unit, aiming for gross proceeds of approximately $4.0 million [1] Group 1: Offering Details - Each unit in the offering consists of one ordinary share (or pre-funded warrant), one Series A warrant, and one Series B warrant [1] - The Series A and Series B warrants are immediately exercisable at an exercise price of $2.00 per share, with Series A expiring in five years and Series B expiring either 30 days after results from the eAArly Detect 2 study or one year from issuance [1] - The offering is expected to close on or about May 21, 2025, subject to customary closing conditions [2] Group 2: Warrant Amendment Agreement - The company has entered into a Warrant Amendment Agreement to reduce the effective strike price of previously issued Series A and Series B Warrants from December 12, 2024, to an amended exercise price of $2.00 [3] Group 3: Regulatory Information - The newly issued securities are being offered under a registration statement on Form F-1, which was declared effective by the SEC on May 16, 2025 [4] - A final prospectus related to the offering will be filed with the SEC, and copies can be obtained from Maxim Group LLC [4] Group 4: Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product being ColoAlert®, a non-invasive test for colorectal cancer marketed in Europe [5] - The company is conducting a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval [5] - Mainz Biomed's product portfolio also includes PancAlert, an early-stage pancreatic cancer screening test [5]